Feed RDY
RD

Dr. Reddy's Laboratories

RDY · NYSE

$11.53 -3.19% (-$0.38)
1M -1.65%
Market Cap ₹920.5B
P/E Ratio 27.75x
Div. Yield 0.72%
ROE 8.94%

Bulios Fair Price

$12.46

8.1% upside

Trenutna cena

$11.53

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica RDY trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
30 /100
Expensive
P/E 27.75x
P/FCF 60.78x
EV/EBITDA 17.65x
Growth
86 /100
Growing
EPS growth 33.72%
Book val. growth 20.50%
Rev. growth 14.94%
Profitability
57 /100
Moderate
Gross margin 50.15%
FCF margin 4.55%
Net margin 9.96%
Quality
40 /100
Average
ROIC 5.83%
Asset turnover 0.58x
ROE 8.94%
Debt
91 /100
Low
Debt/Equity 0.19x
Net debt/EBITDA 1.09x
Current ratio 1.90x
Stability
61 /100
Moderate
Beta 0.25x
Profitable years 6
Rev. volatility 1.55%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RDY
Online

O podjetju

Dr. Reddy's Laboratories Limited (RDY) is an Indian pharmaceutical company specializing in the manufacturing and distribution of a wide range of medicines and generic pharmaceutical products. The company focuses on developing and producing high-quality and affordable medications for patients worldwide. Dr. Reddy's Laboratories has an extensive portfolio of products, including medicines for various therapeutic areas, such as cardiovascular, gastrointestinal, oncology, neurological, and other indications. The company is one of the leading generic pharmaceutical companies and has a strong global presence. Dr. Reddy's Laboratories invests in research and development of new pharmaceutical products and continuously expands its portfolio. Its medications comply with strict quality standards and regulations, making it a trustworthy partner for healthcare institutions, physicians, and patients. Investing in shares of Dr. Reddy's Laboratories Limited (RDY) could present an intriguing opportunity for those who believe in the growing demand for affordable and high-quality generic medicines and the long-term potential of the pharmaceutical industry.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Erez Israeli

Employees

27,527

Headquarters

Hyderabad

Prihajajoči dogodki

23 OKT.

Earnings

Upcoming earnings report

37d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.